ArticleMolecular psychiatry2026
Mapping the path to recovery: the intersection of cortical thickness reductions and serotonin transporter expression in anorexia nervosa.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatial covariance of mGluR5 density and structural degeneration in behavioral variant frontotemporal degeneration.Imaging neuroscience (Cambridge, Mass.) · 2026Article
- Knocking at the Doors of Perception: Relating LSD Effects on Low‐Frequency Fluctuations and Regional Homogeneity to Receptor Densities in fMRI.The European journal of neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Severe reductions in the brain's cortical gray matter thickness (CT) have repeatedly been reported in anorexia nervosa (AN). The underlying mechanisms of these drastic changes remain unclear. Associations with potential underlying neurochemical and metabolic features have not been evaluated. In this study, we investigated whether CT alterations, across the cortical surface, in AN (n = 114) compared to healthy controls (HC; n = 114 age-matched, range 12-29 years old) might be associated with the spatial distribution of neurotransmitter receptors, transporters and/or metabolic glucose uptake (i.e., "chemoarchitecture", based on data from PET binding studies in healthy individuals, as implemented by neuromaps). First, the correlation between CT alterations in AN and chemoarchitecture was evaluated at the group-level. Second, chemoarchitecture was leveraged to compute per-participant correlations of neuroreceptor maps with CT alterations at the individual-level. Correlations with psychiatric symptoms and associations with early weight gain (30-days after admission) were tested. Group-level results were replicated in an external sample. Regions showing substantial cortical thinning in AN were also characterized by higher AChN receptor density and higher glucose metabolism uptake. While CT was comparatively preserved in AN at the group-level in regions with higher HT1a and SERT receptor density, individual participants who exhibited cortical thinning in these regions also reported more severe symptoms (depression and body dissatisfaction) and showed less treatment-related weight gain. These associations may help to define a biological risk signature for AN, possibly allowing for future applications in treatment stratification and/or personalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.